About the Company:

OWC Pharmaceutical Research Corp. is engaged in the business, through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, PTSD, migraines, and of a unique delivery system.

OWC Pharmaceutical Research corp. was incorporated in Delaware on March 7, 2008, under the name Dynamic Applications Corp. On November 25, 2014 the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect the name change with the written consent of the Company’s majority consenting stockholders.

Company Website:


OTC Markets:


Share Structure:

Authorized Shares – 500,000,000
Outstanding Shares – 96,799,955

(As of October 7th, 2016)


Company only has two Notes totaling $51,969, which were mostly converted the past month

No Toxing Financing!  OWCP received a $300,000 non-interest bearing loan with no conversion rights to fund operations!

OWCP an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC (“Medmar”).

According to the terms of the agreement:

The funds will be allocated to complete the development of the Company’s proprietary psoriasis cream; Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC’s Licensed Products in any state in the U.S; The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.

More details:

Medmar has agreed to loan OCW Ltd a total of $300,000 (the “Loan”) on a non-interest bearing basis, with no conversion rights. Medmar will fund the Loan in six equal installments of $50,000 each, as follows: (i) 1st installment was released to OWC Ltd on September 22, 2016; (ii) 2nd installment on October 1, 2016; (iii) 3rd installment on November 1, 2016; (iv) 4th installment on December 1, 2016; (v) 5th installment on January 1, 2017; and (vi) 6th installment on February 1, 2017. The Loan, as noted above, bears no interest, is not convertible, is due in 36 months from the Effective Date, and repayment shall be made only by the set off of royalties payable by Medmar to OWC Ltd.

PR: https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-signs-120000921.html

8K: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11614519

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market

There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.

Based in Israel, an international tech and biotech hub, and the epicenter of medical cannabis research, the OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines. The team is also working on several proprietary drug delivery mechanisms designed to provide consistent and reliable cannabinoid doses to patients more efficiently than smoking or consuming marijuana edibles.

Full Article and Interview: http://www.baystreet.ca/viewarticle.aspx?id=437873

Most Cannabis Research is being done in Israel, according to MerryJane.com and the ‘Cannabis Research Studies‘ documentary.  OWCP is at the epicenter of this work!

OWCP named one of “Top 20 Cannabis Stocks” by Cannabis Investor Magazine! https://finance.yahoo.com/news/cannabis-investor-magazine-june-top-130000276.htm


Obviously this section is opinion based — pure speculation.  Many on Twitter and iHub are pointing out the Market Cap of OWCP in comparison to other Cannabis/Marijuana stocks.  As of this writing, OWCP has a Market Cap of around $6,000,000 while others had reached levels of $17M (MCOA), $35M (PMCB), $41M (CBIS), and even $216M (MJNA).  In other words, they speculate the price has “easy potential” for $0.25 – $0.50/share.  Others go as ‘optimistic’ as $1.00 depending on the November elections. I’m not saying I disagree, as crazier things have happened. Just saying: Never invest/gamble more than you can afford to lose!


(DD compiled by iHub’s “John Kent” with revision/formatting by “FELLER”)